PPD, Inc. to Receive Milestone Payments for First Regulatory Approvals of Priligy(TM) (Dapoxetine) in Finland and Sweden for Treatment of Premature Ejaculation

WILMINGTON, N.C.--(BUSINESS WIRE)--PPD, Inc. (NASDAQ:PPDI) today announced it will receive milestone payments from Janssen-Cilag in connection with the recently announced regulatory approvals in Finland and Sweden of Priligy™ (dapoxetine) for the “on-demand” treatment of premature ejaculation in men 18-64 years of age.
MORE ON THIS TOPIC